Home / Drug shortages / Lidocaine Hydrochloride Injection

Lidocaine Hydrochloride Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., a Pfizer Company

The FDA lists a drug shortage record for Lidocaine Hydrochloride Injection (injection) from Hospira, Inc., a Pfizer Company with status To Be Discontinued. The shortage was first posted on 11/07/2025.

Shortage Details

Status
To Be Discontinued
Company
Hospira, Inc., a Pfizer Company
Package NDC
0409-4903-34
Dosage Form
Injection
Presentation
Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)"
Initial Posting
11/07/2025
Revised Date

FDA data resources